However, our study aimed to determine the association of AHT timing with the survival of patients with HR-positive, ERBB2-negative breast cancer who received AHT but did not receive chemotherapy, and was intended to examine the optimal initiation timing of AHT within the recommended 12 months. This evidence concerns the gene ERBB2 and breast carcinoma.